Spyre Therapeutics, Inc. Share Price & Technical Analysis
SYRE · $74.05 (-0.36%)
Healthcare / Biotechnology
$74.05
-0.36%
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative c…
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
0% return in May, -6% avg return in past 3 year May month.
103% return in 2026, 106% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -2% | 35% | 22% | 48% | 0% | – | – | – | – | – | – | – | 103% |
| 25 | -3% | -10% | -19% | -4% | 1% | -3% | 14% | 0% | 3% | 47% | 25% | 8% | 58% |
| 24 | 18% | 6% | 26% | -13% | 6% | -33% | 16% | 5% | 4% | 11% | -13% | -18% | 15% |
| 23 | 15% | -20% | -30% | -43% | -24% | 253% | 25% | 9% | -12% | -3% | 61% | 14% | 246% |
| 22 | -10% | -37% | -18% | -39% | 10% | -68% | -17% | 28% | 1% | 95% | -60% | 11% | -103% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Strong · Uptrend
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease); and SPY002 and SPY072 anti-TL1A mAbs designed to bind to tumor necrosis factor-like ligand 1A (TL1A). It is also developing SPY003, a clinical-stage program, which is in phase-2 clinical stage designed to bind to interleukin 23 (IL-23); SPY120, a combination of anti-a4ß7 and anti-TL1A mAbs; SPY130, a combination anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. The company was incorporated in 2013 and is based in Waltham, Massachusetts.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$6.41B
P/E ratio
—
52W high
$78.80
52W low
$13.93
Volume
5,74,924
Beta
3.13
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Spyre Therapeutics, Inc. share price today?
- Spyre Therapeutics, Inc. (SYRE) last traded around $74.05 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SYRE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SYRE. Download the app for real-time alerts.
- How can I analyze Spyre Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.